Biochemical variants of Smith-Lemli-Opitz syndrome

Deborah W. Neklason, Katy M. Andrews, Richard I. Kelley, James E. Metherall

Research output: Contribution to journalArticle

Abstract

Smith-Lemli-Opitz (SLO or RSH) syndrome is characterized by multiple congenital anomalies, mental retardation, and defective growth; it results from an inherited defect in the biosynthesis of cholesterol. Patients have elevated plasma concentrations of 7-dehydrocholesterol, the immediate biosynthetic precursor of cholesterol and most also have low circulating levels of cholesterol. To understand better the biochemical basis of clinical variability, we evaluated cholesterol biosynthesis in lymphoblasts from 3 unrelated SLOS patients with distinct phenotypes. One patient has 'type I SLOS', the second has the more severe 'type II SLOS' and the third is classified as atypical and had been postulated to have a defect in sterol transport. The lymphoblasts of each patient show normal subcellular localization of cholesterol and 7-dehydrocholesterol by gradient fractionation. Biochemical differences in the ability of the lymphoblasts to convert 7-dehydrocholesterol to cholesterol are described and correspond to the severity of disease (type II > type I > atypical). Recently, the gene responsible for most SLOS cases (DHCR7) was mapped to chromosome 11 and mutations in DHCR7 were found in each of these patients. The biochemical differences described here likely result from the different mutations observed in DHCR7.

Original languageEnglish (US)
Pages (from-to)517-523
Number of pages7
JournalAmerican Journal of Medical Genetics
Volume85
Issue number5
DOIs
StatePublished - Aug 27 1999

Fingerprint

Smith-Lemli-Opitz Syndrome
Cholesterol
Chromosomes, Human, Pair 11
Mutation
Aptitude
Sterols
Intellectual Disability
Phenotype
Growth

Keywords

  • 3β-hydroxysteroid Δ-reductase
  • 7-dehydrocholesterol
  • Smith-Lemli-Opitz

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Biochemical variants of Smith-Lemli-Opitz syndrome. / Neklason, Deborah W.; Andrews, Katy M.; Kelley, Richard I.; Metherall, James E.

In: American Journal of Medical Genetics, Vol. 85, No. 5, 27.08.1999, p. 517-523.

Research output: Contribution to journalArticle

Neklason, Deborah W. ; Andrews, Katy M. ; Kelley, Richard I. ; Metherall, James E. / Biochemical variants of Smith-Lemli-Opitz syndrome. In: American Journal of Medical Genetics. 1999 ; Vol. 85, No. 5. pp. 517-523.
@article{509f8bc8f94f4e318dd23b1f61bdeff2,
title = "Biochemical variants of Smith-Lemli-Opitz syndrome",
abstract = "Smith-Lemli-Opitz (SLO or RSH) syndrome is characterized by multiple congenital anomalies, mental retardation, and defective growth; it results from an inherited defect in the biosynthesis of cholesterol. Patients have elevated plasma concentrations of 7-dehydrocholesterol, the immediate biosynthetic precursor of cholesterol and most also have low circulating levels of cholesterol. To understand better the biochemical basis of clinical variability, we evaluated cholesterol biosynthesis in lymphoblasts from 3 unrelated SLOS patients with distinct phenotypes. One patient has 'type I SLOS', the second has the more severe 'type II SLOS' and the third is classified as atypical and had been postulated to have a defect in sterol transport. The lymphoblasts of each patient show normal subcellular localization of cholesterol and 7-dehydrocholesterol by gradient fractionation. Biochemical differences in the ability of the lymphoblasts to convert 7-dehydrocholesterol to cholesterol are described and correspond to the severity of disease (type II > type I > atypical). Recently, the gene responsible for most SLOS cases (DHCR7) was mapped to chromosome 11 and mutations in DHCR7 were found in each of these patients. The biochemical differences described here likely result from the different mutations observed in DHCR7.",
keywords = "3β-hydroxysteroid Δ-reductase, 7-dehydrocholesterol, Smith-Lemli-Opitz",
author = "Neklason, {Deborah W.} and Andrews, {Katy M.} and Kelley, {Richard I.} and Metherall, {James E.}",
year = "1999",
month = "8",
day = "27",
doi = "10.1002/(SICI)1096-8628(19990827)85:5<517::AID-AJMG18>3.0.CO;2-1",
language = "English (US)",
volume = "85",
pages = "517--523",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Biochemical variants of Smith-Lemli-Opitz syndrome

AU - Neklason, Deborah W.

AU - Andrews, Katy M.

AU - Kelley, Richard I.

AU - Metherall, James E.

PY - 1999/8/27

Y1 - 1999/8/27

N2 - Smith-Lemli-Opitz (SLO or RSH) syndrome is characterized by multiple congenital anomalies, mental retardation, and defective growth; it results from an inherited defect in the biosynthesis of cholesterol. Patients have elevated plasma concentrations of 7-dehydrocholesterol, the immediate biosynthetic precursor of cholesterol and most also have low circulating levels of cholesterol. To understand better the biochemical basis of clinical variability, we evaluated cholesterol biosynthesis in lymphoblasts from 3 unrelated SLOS patients with distinct phenotypes. One patient has 'type I SLOS', the second has the more severe 'type II SLOS' and the third is classified as atypical and had been postulated to have a defect in sterol transport. The lymphoblasts of each patient show normal subcellular localization of cholesterol and 7-dehydrocholesterol by gradient fractionation. Biochemical differences in the ability of the lymphoblasts to convert 7-dehydrocholesterol to cholesterol are described and correspond to the severity of disease (type II > type I > atypical). Recently, the gene responsible for most SLOS cases (DHCR7) was mapped to chromosome 11 and mutations in DHCR7 were found in each of these patients. The biochemical differences described here likely result from the different mutations observed in DHCR7.

AB - Smith-Lemli-Opitz (SLO or RSH) syndrome is characterized by multiple congenital anomalies, mental retardation, and defective growth; it results from an inherited defect in the biosynthesis of cholesterol. Patients have elevated plasma concentrations of 7-dehydrocholesterol, the immediate biosynthetic precursor of cholesterol and most also have low circulating levels of cholesterol. To understand better the biochemical basis of clinical variability, we evaluated cholesterol biosynthesis in lymphoblasts from 3 unrelated SLOS patients with distinct phenotypes. One patient has 'type I SLOS', the second has the more severe 'type II SLOS' and the third is classified as atypical and had been postulated to have a defect in sterol transport. The lymphoblasts of each patient show normal subcellular localization of cholesterol and 7-dehydrocholesterol by gradient fractionation. Biochemical differences in the ability of the lymphoblasts to convert 7-dehydrocholesterol to cholesterol are described and correspond to the severity of disease (type II > type I > atypical). Recently, the gene responsible for most SLOS cases (DHCR7) was mapped to chromosome 11 and mutations in DHCR7 were found in each of these patients. The biochemical differences described here likely result from the different mutations observed in DHCR7.

KW - 3β-hydroxysteroid Δ-reductase

KW - 7-dehydrocholesterol

KW - Smith-Lemli-Opitz

UR - http://www.scopus.com/inward/record.url?scp=0033609943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033609943&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8628(19990827)85:5<517::AID-AJMG18>3.0.CO;2-1

DO - 10.1002/(SICI)1096-8628(19990827)85:5<517::AID-AJMG18>3.0.CO;2-1

M3 - Article

C2 - 10405455

AN - SCOPUS:0033609943

VL - 85

SP - 517

EP - 523

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

IS - 5

ER -